The researchers developed an exosome-based drug delivery system which employed synergistic miRNA-based autophagy inhibition and 7-coumarin-based chemotherapy for ovarian cancer therapy.
Moffitt Cancer Center researchers have developed a novel reagent that enhances the precision of drug synthesis. This innovative method, published in Nature Communications, introduces a new sulfur fluoride exchange (SuFEx) reagent that allows for highly controlled production of crucial sulfur-based molecules, including sulfinamides, sulfonimidamides and sulfoximines.
Scientists at the Icahn School of Medicine at Mount Sinai have identified a new class of RNAs packed into tiny particles known as extracellular vesicles (EVs) that could revolutionize how cancer and other diseases are diagnosed. The team found that these molecules undergo changes when cancer is present, suggesting their potential as biomarkers for detecting prostate cancer or as targets for therapy.
Study: Living in Disadvantaged Neighborhoods Influences Stress-Related Genes, Which May Contribute to Aggressive Prostate Cancer in African American Men
Taghreed Mohammed Al-Turki, PhD, a postdoctoral researcher in the UNC Lineberger lab of Jack Griffith, PhD, describes her long, difficult, and rewarding journey of becoming a telomere scientist as a first-time mother at the University of North Carolina School of Medicine.
A novel test developed by Johns Hopkins Kimmel Cancer Center investigators could give gastroenterologists insight into which patients with Barrett’s esophagus — a premalignant condition in which parts of the esophagus become damaged by chronic acid reflux — are likely to progress to esophageal cancer or an abnormal collection of cells called high-grade dysplasia.
Mouthwash has long been marketed as an essential hygiene item to prevent bad breath. But what if a mouthwash-based test to detect biomarkers can help predict recurrence of head and neck cancer?
Socioeconomic status, provider-patient relationships and rural living environments have been found to affect cancer screening behaviors for people LBGTQIA+ individuals, according to a recent study from Callie Kluitenberg Harris, a Ph.D. candidate at the Michigan State University College of Nursing.
University Hospitals (UH) Seidman Cancer Center hematologist-oncologist Leland Metheny, MD, is leading the trial. He says in the two years since the foundational pre-clinical work was completed, the team has shown that it’s feasible to manufacture BAFF CAR T-cells for human subjects.
A new Cleveland Clinic study has identified diet-derived molecules called metabolites as main drivers of young-onset colorectal cancer risk, especially those associated with red and processed meat. The NPJ Precision Oncology report, which analyzed metabolite and microbiome datasets, highlighted that one of the best ways a younger (<60 years) adult can prevent colorectal cancer is to discuss their diet with their doctor.
Contrary to how tumors operate while still in the kidney, metastatic kidney cancers rely heavily on mitochondrial metabolism, according to new research from Children’s Medical Center Research Institute at UT Southwestern (CRI) published in Nature.
Researchers aim to transform cancer survivorship care in the U.S. by enhancing the adoption of shared delivery models
access_time Embargo lifts in 2 days
Embargo will expire:
19-Aug-2024 5:00 PM EDT
Released to reporters: 13-Aug-2024 2:00 PM EDT
A reporter's PressPass is required to
access this story until the embargo expires on 19-Aug-2024 5:00 PM EDT
The Newswise PressPass gives verified journalists access to embargoed stories.
Please log in to complete a presspass application.
If you have not yet registered, please Register. When you
fill out the registration form, please identify yourself as a reporter in order to
advance to the presspass application form.
In the past two decades, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, showing promising results against various solid tumors. This study reviews recent developments in ICIs, focusing on new targets like T cell immunoreceptor with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and lymphocyte activation gene-3 (LAG-3). These targets aim to overcome resistance mechanisms limiting the effectiveness of current therapies, such as anti-PD-1 and anti-CTLA-4. By identifying and developing these new ICIs, researchers hope to improve treatment outcomes and provide new therapeutic options for cancer patients.
New research from Memorial Sloan Kettering Cancer Center (MSK) found patients with non-small cell lung cancer brain metastases may benefit from up-front stereotactic radiosurgery; identified a connection between antibiotic use and autoimmune diseases; and uncovered a previously unknown structural role for messenger RNAs in the cytoplasm of cells.
Faculty members from the Faculty of Engineering and Faculty of Medicine, Chulalongkorn University, jointly developed DeepGI, an AI innovation used in gastrointestinal endoscopy, for accurate cancer detection. The technology is in use at King Chulalongkorn Memorial Hospital and has received global recognition in the GI endoscopy doctors meeting ENDO 2024 in South Korea.
In a notable advancement for Hodgkin's lymphoma (HL), recent research has introduced sophisticated therapeutic strategies designed to significantly boost patient outcomes.
Susan G. Komen applauds the Illinois General Assembly and Governor J.B. Pritzker on the passage of SB 2697, which provides expanded coverage of genetic testing for the breast cancer community.